US20060083731A1 - Use of an enzyme for the manufacture of an agent for controlling bacterial infection - Google Patents

Use of an enzyme for the manufacture of an agent for controlling bacterial infection Download PDF

Info

Publication number
US20060083731A1
US20060083731A1 US11/289,364 US28936405A US2006083731A1 US 20060083731 A1 US20060083731 A1 US 20060083731A1 US 28936405 A US28936405 A US 28936405A US 2006083731 A1 US2006083731 A1 US 2006083731A1
Authority
US
United States
Prior art keywords
cellulase
bacterial infection
method according
chickens
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/289,364
Inventor
Michael Bedford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finnfeeds International Ltd
Original Assignee
Finnfeeds International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB9715214A priority Critical patent/GB2327345B/en
Priority to GBGB/9715214.4 priority
Priority to PCT/EP1998/004440 priority patent/WO1999003497A1/en
Priority to US09/487,383 priority patent/US7011964B2/en
Application filed by Finnfeeds International Ltd filed Critical Finnfeeds International Ltd
Priority to US11/289,364 priority patent/US20060083731A1/en
Publication of US20060083731A1 publication Critical patent/US20060083731A1/en
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/189Enzymes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/47The waterborne disease being caused by a bacteria the bacteria being Campylobacter jejuni, i.e. Campylobacteriosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/481The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis

Abstract

Xylanase or a cellulase for the manufacture of an agent for the treatment and/or prophylaxis of bacterial infection in an animal caused by Salmonella, Campylobacter or Clostridium perfringens. It is preferred that xylanase is used in combination with wheat to form an animal feed. Such a diet is particularly effective in controlling Campylobacter and Salmonella in chickens. The use provided by the present invention affords an alternative to antibiotics when controlling bacterial infection in animals. This leads to considerable health, environmental and economic benefits.

Description

    REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of application Ser. No. 09/487,383, filed Jan. 18, 2000, which is a continuation of International Application No. PCT/EP98/04440, filed Jul. 16, 1998, the disclosures of which applications are incorporated by reference herein in their entireties, and which claim foreign priority of United Kingdom Application No. GB/9715214.4, filed Jul. 18, 1997.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention is directed to the use of an enzyme for the manufacture of an agent for the treatment and/or prophylaxis of a bacterial infection.
  • 2. Discussion of Background Information
  • The farming of many different types of animals is important throughout the world for the production of food for human consumption. When the animals are reared, they come into contact with a variety of infection-causing bacteria, such as Campylobacter and Salmonella. In some cases these bacteria may spread directly from animals to humans (zoonosis). Accordingly, it is necessary from an economic, environmental and health perspective that such bacterial infection is prevented or eradicated in the animal prior to human consumption to prevent the spread of the disease to humans.
  • The domestic animal of particular, but not exclusive, concern with regard to zoonosis is the chicken. Campylobacter and Salmonella are particularly prevalent in the chicken. The bacteria are transmitted to the bird in a variety of ways, including through feed, water, litter and vermin. The bacteria initially infect the caecae of the chicken. The disease then progresses to the small intestine where infestation may cause loss of weight in the bird. A particular problem with the chicken is that it is almost impossible to eviscerate in a sterile manner with the result that bacteria inhabiting the intestines will invariably be transmitted to the saleable carcass. Accordingly the potential for zoonosis is great, unless the carcass is handled or cooked properly. The cost of human infection caused by eating improperly treated chicken is significant in terms of both time and lives.
  • Accordingly, presently there is a demand for improved methods of reducing bacterial infection in animals such as the chicken, in particular those intended for human consumption.
  • Various solutions to the problem of bacterial infection have been proposed. Current methods of control include the application of antibiotics, feed sterilisation and careful and controlled handling and cooking of the carcass after slaughter. Feed sterilisation has proved ineffective in the absence of a sterile rearing environment (which is impractical) whilst controlled handling and cooking cannot be relied upon in every instance. The application of antibiotics has proved unpopular with consumer groups wishing to reduce the quantity of potentially harmful chemicals in food. The use of antibiotics has the additional problem that if they are not introduced into the animal in a properly controlled manner, antibiotic-resistant strains of bacteria can be created, making such infections more difficult to treat in the future. The prophylactic use of antibiotics in animal feed has thus been regulated in some countries (notably Sweden and Finland) effectively reducing the available methods of control. Indeed no single method provides a barrier which completely prevents bacteria being transferred from the animal to humans.
  • As an alternative to the above methods it has been proposed in Poultry Science, 1994 73:402-407, to introduce flora into chickens to compete with the bacteria causing the infection. Such mucosal competitive exclusion flora (MCE) were found to reduce the level of Campylobacter jejuni infection in chickens. However, the competitive exclusion treatment is not found to be consistently effective, its efficacy varying from animal to animal.
  • JP-A-81-73055 discloses animal feeds intended to prevent contamination with Salmonella. The feeds are indicated to contain partially decomposed mannan in the form of mannose polysaccharides. These are produced by degradation of mannan with an enzyme, produced by micro-organisms. The resulting feed was found to be moderately effective against Salmonella in chickens, but is not effective against Campylobacter.
  • U.S. Pat. No. 5,124,262 discloses a mannose isomerase enzyme used for converting fructose to mannose. The mannose thus produced is taught to be useful in feeds, for inhibiting the growth of Salmonella in chickens.
  • In Bamboo J. 1993, pp. 29-35, xylan prepared from steamed bamboo grass is mentioned as inhibiting the growth of various human intestinal bacteria. In particular the xylan is indicated to be effective against Salmonella. However, the inhibition effect is reversed after a period of 24 hours.
  • The above methods have proved more desirable from an environmental and health point of view, than the administration of antibiotics. However, none have proved effective enough to be commercially viable.
  • WO 93/01800 discloses the use of a protease for the preparation of a medicament effective against intestinal pathogens in animals. The pathogens of interest include Campylobacter. However, there is no mention of enzymes other than proteases being useful in controlling animal pathogens.
  • EP-A-0 681 787 discloses use of a carbohydrase or protease for the manufacture of an agent for the treatment of Coccidiosis. However, Coccidiosis in chickens is caused by protozoal oocytes. The document does not indicate how bacterial pathogens in chickens, or other animals, can be controlled.
  • SUMMARY OF THE INVENTION
  • Accordingly, one object of the present invention is to provide an agent which can be used for controlling bacterial infection that is more effective than the presently available agents, and in particular than those described in the prior art acknowledged above. A further object of the present invention is to provide an agent which can be used for controlling bacterial infection that is less harmful to the environment, less expensive than the presently available agents, and has advantages for human health.
  • Accordingly, the present invention provides the use of a xylanase or a cellulase for the manufacture of an agent for the treatment and/or prophylaxis of bacterial infection in an animal caused by Salmonella, Campylobacter or Clostridium perfringens.
  • A preferred cellulase is β-glucanase.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the effect of three diets on Campylobacter colonisation in 12-day old chicks. Three different dilution levels of the initial stock solution of Campylobacter were used to introduce the pathogen to the chicks. The results are presented as mean scores of positive caecae and represent the combined results of two flocks A and B comprising a total of 108 birds (12 per dilution for each of the three diets);
  • FIG. 2 shows the results of FIG. 1, but for flock A alone;
  • FIG. 3 shows the results of FIG. 1, but for flock B alone;
  • FIG. 4 shows similar results to FIG. 1, but at three alternative dilution levels of the initial Campylobacter stock solution. The results are presented as mean counts log10CFU(Colony Forming Units)/ml;
  • FIG. 5 shows the results of FIG. 4, but for flock A alone;
  • FIG. 6 shows the results of FIG. 4, but for flock B alone;
  • FIG. 7 shows the effect of three diets on Campylobacter colonisation of the small intestine and caecae of 17-day old chicks. The results are presented as mean counts log10CFU/ml, and represent the combined results of two flocks A and B comprising a total of 72 birds (12 per treatment) for each of the three diets;
  • FIG. 8 shows the results of FIG. 7, but for flock A alone;
  • FIG. 9 shows the results of FIG. 7, but for flock B alone;
  • FIG. 10 shows a comparison of the weight of 1, 5, 12, 19, 25 and 33-day old chicks (20 in total) dosed with Campylobacter jejuni, and similar chicks (25 in total) which have not been dosed, the chicks all being fed a wheat-based diet;
  • FIG. 11 shows similar results to those of FIG. 10, but for chicks on a wheat plus xylanase diet;
  • FIG. 12 shows similar results to those of FIG. 10, but for chicks on a maize-based diet; and
  • FIG. 13 shows the effect of two different diets (wheat and wheat plus xylanase) on Salmonella enteritidis colonisation in 14 day old chicks. The results are presented as mean counts log10CFU/ml. Tests were carried out on two flocks, A and B, comprising a total of 48 birds, 24 per diet.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The advantage of using feeds containing a xylanase or a cellulase for rearing animals is that the amount of antimicrobial drugs which have previously been routinely incorporated into their diet can be reduced, or in some cases omitted entirely. This enables considerable economic savings to be achieved in view of the relative expense of antibiotics. In countries where such drugs are banned, it represents a totally new approach to the control of bacterial diseases.
  • When omitting antibiotics from an animal's diet there are several potential further benefits. It has previously been necessary to withdraw antibiotics from the animal's diet for a certain time prior to slaughter. This ensures that the meat is relatively free from such drugs and thus fit for human consumption. In contrast, if antibiotics are entirely omitted from an animal's diet, as may be achieved with the present invention, then the animal can be slaughtered at any age rather than after a certain withdrawal period. This affords the farmer improved flexibility and removes the risk of animals becoming infected shortly prior to slaughter. Further, meat and eggs can be guaranteed free of antibiotics. Such meat and eggs have a market advantage as compared to products which cannot support such a guarantee.
  • Even if the enzyme added to the animal's diet only enables the level of inclusion of antibiotics to be reduced, then the overall cost of controlling bacterial infection will be reduced. Synergy or potentiation may extend the useful life of the antibiotic.
  • The present invention also has benefits for human health. Its use reduces the selection pressure for antibiotic-resistant strains of bacteria, by allowing antibiotics to be removed from animal feed. Accordingly, more antibiotic-susceptible strains will be present in the gut of the animal, thereby ensuring a more likely positive outcome in the event of antibiotics being used on the equivalent human condition.
  • The xylanase or cellulase enzyme to be used in the feeds can be formulated as a pre-mix together with any other enzymes to be included. The pre-mix can be added to the raw materials before feed manufacture, during feed manufacture or as a final step once the feed is otherwise ready for use. It is possible to add the enzyme directly as a liquid to a feed material pre-formed as pellets or as a mash.
  • It is also possible to include the enzyme in the animal's diet by incorporating it into a second (and different) feed or drinking water which the animal also has access to. Accordingly, it is not essential that the enzyme is incorporated into the feed itself, although such incorporation forms a particularly preferred aspect of the present invention.
  • If the enzyme is incorporated into a feed, then this preferably comprises at least 25% by weight of a cereal, and more preferably at least 35% by weight of the cereal. The cereal may be any one or more of wheat, maize, rye, barley, oats, triticale, rice, and sorghum. It is particularly preferred that the cereal is wheat.
  • Although the cereal component of a cereal-based diet constitutes a source of protein, it is usually necessary to include sources of supplementary protein in the diet, such as those derived from fishmeal, meatmeal or vegetables. These sources of supplementary protein may constitute up to 50% by weight of the animal feed. Sources of vegetable protein include at least one of full fat soybean, rapeseed, canola, soybean meal, rapeseed meal and canola meal.
  • If the enzyme is incorporated into a feed, then this is preferably added in a relative amount of 0.0001-10 g of the enzyme per kilo of the feed, more preferably 0.001-1 g/kg and most preferably 0.01-0.1 g/kg.
  • The xylanase for use in this invention can be obtained from a fungus, such as Trichoderma, Aspergillus, Humicola, or Neocallimastix. Alternatively, the xylanase can be obtained from a bacterium, such as Bacillus, Streptomyces, Clostridium, or Ruminococcus.
  • The present invention is particularly effective against strains of Salmonella and Campylobacter, and especially Salmonella enteritidis and Campylobacter jejuni. Another bacterium against which the invention is effective is Clostridium perfringens.
  • Bacterial infection can be treated or prevented in accordance with the present invention in a wide variety of animals, but use of the invention is particularly preferred in domestic animals and farm livestock. Animals which may in particular benefit from the invention include poultry (such as chickens, turkeys, ducks and geese), ruminants (such as cattle, horses and sheep), swine (pigs), cats, dogs, rodents (such as rabbits) and fish. The invention is particularly useful in broiler chickens.
  • The most preferred combinations of feed and enzyme include wheat plus xylanase, maize plus xylanase and barley plus β-glucanase.
  • The enzymes used in the present invention fall within a general Class called polysaccharidases. Their substrates are structural polysaccharides such as xylans and β-glucans that occur as an integral part of the cell wall of most land plants. These polysaccharides are not found in animal cells, and are not to be expected to have any activity against proteins. Because these enzymes attack polysaccharides found in plant cell walls, the only possible substrates for these enzymes in the gastrointestinal tract of an animal are contained in cereal-based feeds. It is therefore speculated that the beneficial effects of the xylanase or cellulase on bacterial infection result somehow from the degradation products which they produce such as xylan or β-glucan derived from a cereal-based diet.
  • As previously mentioned, WO 93/01800 discloses the use of a protease for the preparation of a medicament effective against intestinal pathogens in animals. It is well established that such pathogens mediate their infectivity by binding to receptors on the surface of intestinal epithelial cells via antigenic protein or glycoprotein molecules expressed on the pathogen's cell surface. It is suggested that the protease enzyme prevents binding of the pathogen cells to the intestinal epithelium by destroying these proteinaceous receptor/adhesion sites to which the pathogen must bind if it is to cause an infection. The protease ensymes mentioned in this reference would be predicted to destroy proteins on the lumenal surface of intestinal epithelial cells in a non-specific manner, but would not be expected to attack substrates other than proteins. Accordingly, the activity of the proteases disclosed in this reference is fundamentally different from the activity of the enzymes used in the present invention. A skilled person could not have predicted the utility of the present enzymes against bacterial infection based upon the activity of proteases disclosed in WO 93/01800.
  • The invention will now be described in more detail according to the following Examples.
  • EXAMPLES General Methodology
  • Wheat and maize diets were prepared having the following formulations: TABLE 1 Wheat diet Ingredients Percent Soft Wheat 58.83 Soybean ml 48 32.49 Soy oil 4.49 Salt 0.30 Sodium Bicarbonate 0.12 DL Methionine 0.14 Limestone 1.37 Di-calcium Phosphate 1.26 Vitamins/Minerals 1.00 TOTAL 100.00
  • TABLE 2 Maize diet Ingredients Percent Maize 58.38 Soybean ml 48 37.30 Soy oil 2.96 Salt 0.30 Sodium Bicarbonate 0.16 DL Methionine 0.13 Limestone 1.22 Di-calcium Phosphate 1.55 Vitamins/Minerals 1.00 TOTAL 100.00
  • Animal feeds were prepared by introducing a cereal carrier containing approximately 3 mg enzyme protein/kg into the wheat diet at a concentration of 1 kg of enzyme and carrier per tonne of wheat diet. The final concentration of enzyme protein in the feed was thus approximately 3 mg per tonne. The xylanase was obtained from Trichoderma longibrachiatum. Broiler chicks were fed the wheat plus xylanase diet from hatching. For comparison purposes, separate flocks of chicks were fed with the wheat diet and the maize diet without the addition of xylanase. A challenge model was used, whereby 0.2 ml of a stock solution of C. jejuni were introduced to each chick by syringe at day 7 from hatching. The dilution level of the stock solution was varied, from 10−1 (high challenge) to 10−6 (low challenge, similar to natural conditions). The undiluted stock solution contained approximately 104 CFU per 0.2 ml. The caecae of the chicks were examined for damage due to the Campylobacter at varying ages.
  • Example 1
  • FIGS. 1-6 show the effect of the diets on Campylobacter colonisation in 12-day old chicks. In each case two flocks, A and B, were tested to minimise the effect of environmental variance on the results. In each case it is clearly evident that a wheat plus xylanase diet is effective in reducing the level of Campylobacter in the caecae of the chicks in comparison with a maize diet. Additionally, at Campylobacter stock solution dilution levels of 10−3 or lower (i.e. approaching more natural conditions), the wheat plus xylanase diet becomes considerably more effective than the wheat diet alone. Thus, in FIG. 1, for the wheat plus xylanase diet at a Campylobacter stock solution dilution of 10−6, a mean score of 0.5 positive caecae was observed. The equivalent scores for diets lacking xylanase were approximately 1.5 and 2.5.
  • Example 2
  • FIGS. 7-9 demonstrate the effectiveness of the diets on Campylobacter colonisation of the small intestine and caecae of 17-day old chicks from two flocks. The effect of the wheat plus xylanase diet on reducing the Campylobacter colonisation of the caecae of the chicks is evident as already demonstrated in Example 1. However this reduction is even more marked as regards the small intestine. Accordingly, in FIG. 7 the mean count log10CFU in the small intestine measured for chicks on the wheat and xylanase diet was less than 4. The equivalent counts for the diets not containing xylanase were found to be approximately 6, i.e. 100-fold higher.
  • Example 3
  • FIGS. 10-12 depict a comparison of the effect of different diets on the weight of 1, 5, 12, 19, 25 and 33-day old chicks. FIG. 10 shows the results for the wheat-based diet, FIG. 11 the results for the wheat plus xylanase-based diet and FIG. 12 the results for the maize-based diet. The weight of the chicks in each case is reduced by dosing with Campylobacter. However, those chicks to which Campylobacter has been introduced gain weight more quickly on the wheat plus xylanase diet than on either of the other diets.
  • Example 4
  • FIG. 13 demonstrates the effectiveness of the wheat and wheat plus xylanase diets on Salmonella enteritidis colonisation of the caecae of 14-day old chicks from two flocks, A and B. The methodology employed in these experiments was identical to that employed for the Campylobacter experiments described above, except that the undiluted stock solution of Salmonella enteritidis contained approximately 105 CFU per 0.2 ml. The effect of the wheat plus xylanase diet on reducing the Salmonella colonisation of the caecae of the chicks is clearly evident. Thus, in flock B, the chicks on the wheat diet were found to have a mean count log10CFU/ml of approximately 7. However, the chicks from flock B on the wheat plus xylanase diet were found to have a much lower log10CFU/ml of approximately 4 (1000-fold lower).
  • The above Examples clearly show a reduction in bacterial infection in the gut due to the inclusion of xylanase in the diet. Similar results have been observed when using a cellulase such as a β-glucanase. This indicates that the use provided by the present invention significantly reduces the ability of certain bacteria to colonise the caecae which in turn prevents migration of the bacteria to the small intestine. Accordingly, since it has a reduced level of infection, the growth rate of the animal is increased, leading to economic benefits. The reduction in contamination rate also has obvious benefits to human health and the replacement of antibiotics by such diets has clear environmental benefits.

Claims (16)

1. A method for treatment of a bacterial infection in chickens having bacterial infection in the absence of therapeutic or prophylactic amounts of antimicrobial drugs, the bacterial infection caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof, the method comprising:
feeding the chickens a diet comprising a feed including a cellulase and at least about 25% by weight of a cereal selected from the group consisting of wheat, maize, rye, barley, oats, triticale, rice, sorghum and mixtures thereof, the diet being effective for treatment of bacterial infection in the chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof, and the cellulase being present in an amount effective for treatment of the bacterial infection in the absence of an antimicrobial drug or in the presence of an antimicrobial drug at a concentration that in the absence of the cellulase is not effective for treatment of bacterial infection in chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof, and the diet not containing an antimicrobial drug or containing an antimicrobial drug at a concentration that is not effective in the absence of the cellulase for treatment of bacterial infection in chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof.
2. The method according to claim 1 wherein the cellulase is fed to the chickens in an amount of about 0.0001 to about 10 grams of cellulase per kg of the feed.
3. The method according to claim 1 wherein the cellulase is fed to the chickens in an amount of about 0.001 to about 1 gram of cellulase per kg of the feed.
4. The method according to claim 1 wherein the cellulase is fed to the chickens in an amount of about 0.01 to about 0.1 gram of cellulase per kg of the feed.
5. The method according to claim 1 wherein the cereal is wheat.
6. The method according to claim 1 wherein the cellulase is β-glucanase.
7. The method according to claim 6 wherein the cereal comprises wheat.
8. The method according to claim 1 wherein the diet is fed to the chickens without a withdrawal period prior to slaughtering of the chickens.
9. The method according to claim 1 wherein said diet does not contain an antimicrobial drug.
10. The method according to claim 1 wherein said diet contains an antimicrobial drug at a concentration that is not effective for treatment and/or prophylaxis of bacterial infection in chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof in the absence of the cellulase.
11. The method according to claim 8 wherein said diet does not contain an antimicrobial drug.
12. The method according to claim 8 wherein said diet contains an antimicrobial drug at a concentration that is not effective for treatment and/or prophylaxis of bacterial infection in chickens caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof in the absence of the cellulase.
13. A method for treating a bacterial infection in a chicken caused by bacteria selected from the group consisting of Salmonella, Campylobacter, Clostridium perfringens, and mixtures thereof, the method comprising:
feeding the chicken an animal feed which comprises a cellulase and at least about 25% by weight of a cereal selected from the group consisting of wheat, maize, rye, barley, oats, triticale, rice, sorghum and mixtures thereof, the cellulase being included in the animal feed in an amount effective for treating the bacterial infection.
14. The method according to claim 13 wherein the cereal comprises wheat.
15. The method according to claim 13 wherein the cellulase is β-glucanase.
16. The method according to claim 15 wherein the cereal comprises wheat.
US11/289,364 1997-07-18 2005-11-30 Use of an enzyme for the manufacture of an agent for controlling bacterial infection Abandoned US20060083731A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB9715214A GB2327345B (en) 1997-07-18 1997-07-18 Use of an enzyme for manufacturing an agent for controlling bacterial infection
GBGB/9715214.4 1997-07-18
PCT/EP1998/004440 WO1999003497A1 (en) 1997-07-18 1998-07-16 Use of an enzyme for the manufacture of an agent for controlling bacterial infection
US09/487,383 US7011964B2 (en) 1997-07-18 2000-01-18 Use of an enzyme for the manufacture of an agent for controlling bacterial infection
US11/289,364 US20060083731A1 (en) 1997-07-18 2005-11-30 Use of an enzyme for the manufacture of an agent for controlling bacterial infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/289,364 US20060083731A1 (en) 1997-07-18 2005-11-30 Use of an enzyme for the manufacture of an agent for controlling bacterial infection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/487,383 Division US7011964B2 (en) 1997-07-18 2000-01-18 Use of an enzyme for the manufacture of an agent for controlling bacterial infection

Publications (1)

Publication Number Publication Date
US20060083731A1 true US20060083731A1 (en) 2006-04-20

Family

ID=10816111

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/487,383 Expired - Fee Related US7011964B2 (en) 1997-07-18 2000-01-18 Use of an enzyme for the manufacture of an agent for controlling bacterial infection
US11/289,364 Abandoned US20060083731A1 (en) 1997-07-18 2005-11-30 Use of an enzyme for the manufacture of an agent for controlling bacterial infection

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/487,383 Expired - Fee Related US7011964B2 (en) 1997-07-18 2000-01-18 Use of an enzyme for the manufacture of an agent for controlling bacterial infection

Country Status (15)

Country Link
US (2) US7011964B2 (en)
EP (1) EP0999851B1 (en)
JP (1) JP2001510167A (en)
KR (1) KR20010021993A (en)
AT (1) AT210457T (en)
AU (1) AU733314B2 (en)
BR (1) BR9810603A (en)
CA (1) CA2296356A1 (en)
DE (1) DE69802938T2 (en)
DK (1) DK0999851T3 (en)
ES (1) ES2169924T3 (en)
GB (1) GB2327345B (en)
PL (1) PL342188A1 (en)
PT (1) PT999851E (en)
WO (1) WO1999003497A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2444413A1 (en) 2006-08-04 2012-04-25 Verenium Corporation Methods for oil or gas well drilling, washing and/or fracturing
WO2014207435A1 (en) 2013-06-25 2014-12-31 Ucl Business Plc Anti-microbial agents and uses therefor

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
CN100391357C (en) * 2002-02-26 2008-06-04 东莞市豪发生物工程开发有限公司 Bacilli fungi mixed fermentation for producing microbial formulation and compound enzyme feed additive
CN101967490B (en) 2002-06-14 2014-07-16 先正达公司 Xylanases, nucleic adics encoding them and methods for making and using them
EP2404931A1 (en) 2003-07-02 2012-01-11 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
JP5189989B2 (en) * 2005-12-15 2013-04-24 イーライ リリー アンド カンパニー Enzymes for immunological stress reduction
DK1989302T3 (en) 2006-02-14 2018-07-23 Bp Corp North America Inc Xylanases, nucleic acid coding them and procedures for their preparation and use
CN103757036B (en) 2007-10-03 2019-10-01 维莱尼姆公司 Zytase, the nucleic acid and its methods for making and using same for encoding them
EP2254591B1 (en) * 2008-02-08 2017-07-26 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124262A (en) * 1990-02-28 1992-06-23 Amano Pharmaceutical Co., Ltd. Mannose isomerase and process for mannose production using it
US5314692A (en) * 1987-08-24 1994-05-24 Cultor Ltd. Enzyme premix for feed and method
US5470725A (en) * 1989-02-16 1995-11-28 Carlsberg A/S Thermostable (1,3-1,4)-β-glucanase
US5612055A (en) * 1994-08-19 1997-03-18 Genecor International, Inc. Enzyme feed additive and animal feed
US5624678A (en) * 1994-05-10 1997-04-29 Finnfeeds International Limited Method and composition for treatment and/or prophylaxis of coccidiosis
US5817500A (en) * 1995-01-26 1998-10-06 Novo Nordisk A/S Animal feed additives
US5902581A (en) * 1995-12-04 1999-05-11 Genencor International, Inc. Xylanase from acidothermus cellulolyticus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2321283B1 (en) 1975-05-14 1978-08-04 Parcor
FR2448351B1 (en) * 1979-02-09 1983-03-04 Brisou Jean
CA1321962C (en) * 1985-03-20 1993-09-07 Aizo Matsushiro Dental caries preventive preparations and method for preparing said preparations
EP0596962A4 (en) 1991-07-24 1997-01-15 Enzacor Pty Ltd Therapeutic compositions and methods.
GB2261877A (en) * 1991-11-21 1993-06-02 Kyowa Hakko Kogyo Kk Animal feed additive comprising enzyme and amino acid
GB9200891D0 (en) * 1992-01-16 1992-03-11 Mann Stephen P Formulation of microorganisms
GB9406317D0 (en) * 1994-03-30 1994-05-25 Finnfeeds Int Ltd Use of an enzyme for assisting an animal to digest protein
AUPN033894A0 (en) * 1994-12-29 1995-01-27 Rowe, J.B. Prevention of adverse behaviour in humans and animals
JPH0984529A (en) * 1995-09-27 1997-03-31 Kohjin Co Ltd Cattle and poultry feed containing mannan originated from microorganism
SE510498C2 (en) * 1996-02-14 1999-05-31 Biofeed Thailand Co Ltd An animal feed additive containing microorganisms
WO1997038670A1 (en) * 1996-04-16 1997-10-23 Novo Nordisk A/S Compositions for the removal of dental plaque

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314692A (en) * 1987-08-24 1994-05-24 Cultor Ltd. Enzyme premix for feed and method
US5470725A (en) * 1989-02-16 1995-11-28 Carlsberg A/S Thermostable (1,3-1,4)-β-glucanase
US5124262A (en) * 1990-02-28 1992-06-23 Amano Pharmaceutical Co., Ltd. Mannose isomerase and process for mannose production using it
US5624678A (en) * 1994-05-10 1997-04-29 Finnfeeds International Limited Method and composition for treatment and/or prophylaxis of coccidiosis
US5612055A (en) * 1994-08-19 1997-03-18 Genecor International, Inc. Enzyme feed additive and animal feed
US5817500A (en) * 1995-01-26 1998-10-06 Novo Nordisk A/S Animal feed additives
US5902581A (en) * 1995-12-04 1999-05-11 Genencor International, Inc. Xylanase from acidothermus cellulolyticus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2444413A1 (en) 2006-08-04 2012-04-25 Verenium Corporation Methods for oil or gas well drilling, washing and/or fracturing
WO2014207435A1 (en) 2013-06-25 2014-12-31 Ucl Business Plc Anti-microbial agents and uses therefor

Also Published As

Publication number Publication date
EP0999851A1 (en) 2000-05-17
JP2001510167A (en) 2001-07-31
US20010046494A1 (en) 2001-11-29
DE69802938D1 (en) 2002-01-24
KR20010021993A (en) 2001-03-15
CA2296356A1 (en) 1999-01-28
WO1999003497A1 (en) 1999-01-28
US7011964B2 (en) 2006-03-14
DK999851T3 (en)
DE69802938T2 (en) 2002-08-14
DK0999851T3 (en) 2002-04-08
GB9715214D0 (en) 1997-09-24
AU8862398A (en) 1999-02-10
AT210457T (en) 2001-12-15
AU733314B2 (en) 2001-05-10
BR9810603A (en) 2000-07-11
PT999851E (en) 2002-05-31
GB2327345A (en) 1999-01-27
ES2169924T3 (en) 2002-07-16
EP0999851B1 (en) 2001-12-12
GB2327345B (en) 1999-06-23
PL342188A1 (en) 2001-05-21

Similar Documents

Publication Publication Date Title
Sørum et al. Resistance to antibiotics in the normal flora of animals
Bedford Removal of antibiotic growth promoters from poultry diets: implications and strategies to minimise subsequent problems
Samli et al. Effects of Enterococcus faecium and dried whey on broiler performance, gut histomorphology and intestinal microbiota
Pluske Feed-and feed additives-related aspects of gut health and development in weanling pigs
Ferket Alternatives to antibiotics in poultry production: responses, practical experience and recommendations
Sarica et al. Use of an antibiotic growth promoter and two herbal natural feed additives with and without exogenous enzymes in wheat based broiler diets
Jensen The impact of feed additives on the microbial ecology of the gut in young pigs
Doyle et al. Reducing the carriage of foodborne pathogens in livestock and poultry
ES2567296T3 (en) Procedure to use a strain of Bacillus subtilis to enhance animal health
AU667070B2 (en) Formulation and use of microorganisms in treating livestock
Falcão-e-Cunha et al. Alternatives to antibiotic growth promoters in rabbit feeding: a review.
Thomke et al. Growth promotants in feeding pigs and poultry. III. Alternatives to antibiotic growth promotants
George et al. Virginiamycin effects on controlling necrotic enteritis infection in chickens
Roguet et al. Selection and use of feeding sites and feeding stations by herbivores: a review
US6166086A (en) Small molecules that increase the conversion of food to body weight gain
DE69830302T2 (en) Mannose-containing feed agent and method for the production thereof
EP0881886B1 (en) Animal feed
Wales et al. Chemical treatment of animal feed and water for the control of Salmonella
US5985891A (en) Prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals by the application of antibiotics
BRPI0610965A2 (en) composition for consumption by an animal, methods for improving the palatability of a composition for consumption by an animal, for increasing the frequency of ingestion or ingestion rate of a composition for consumption by an animal, and for making a composition for animal consumption, product, kit, and means for communicating information about or instructions for mixing and administering an animal composition having improved palatability to an animal
US20120082754A1 (en) Mycellated grain and other myceliated agricultural materials to be used as animal food supplement
Khattak et al. Enzymes in poultry nutrition
Abdulrahim Effect of Lactobacillus acidophilus and zinc bacitracin as dietary additives for broiler chickens
RU2080386C1 (en) Multienzyme composition for cattle breeding
Yasar et al. Enzyme supplementation of dry and wet wheat-based feeds for broiler chickens: performance and gut responses

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION